

## Lupin to enable patients' access to affordable and innovative medicines

*Yash Ved, Mumbai, Saturday, December 12, 2020, 08:00 Hrs [IST]*

The Indian pharmaceutical major Lupin Limited is planning to launch Nepexto biosimilar etanercept across European markets and the company will be filing Pegfilgrastim during this fiscal to keep advancing its robust biosimilars pipeline.

The company's mission is to enable patients' access to affordable and innovative medicines.

"Our Q2 US numbers were better than expected. We have sustained generic sales in the US with the exception of Q1FY '21 due to demand softening of our retail products due to COVID as well as our recall of metformin products. Since then, we have successfully relaunched glumetza, our lead metformin product and have stabilized the base business," stated Alok Sonig, CEO – US generics and global head generics R&D & biosimilars at Lupin Limited.

Sonig added that the new launches of gProAir, gApriso, gVimovo, and gTykerb will accelerate growth momentum in the quarters to come.

The company stated that it has signed an agreement with ForDoz Pharma to market and distribute 2 complex injectable assets in the US. These assets are in already advanced stages of development. The two assets are in the oncology and anti-infective therapeutic areas.

The company stated that it will leverage existing commercial infrastructure for commercializing these limited-competition assets.

The company has also ramped up albuterol supply since its launch in September, especially given the supply disruption caused by a competitor's product recall.

Sonig said that Lupin will continue to ramp up quarter-on-quarter and is committed to accelerating access to its product for patients in need.

"In the last fiscal, we invested nearly 10% of our revenue into research & development. At present, our R&D spend as a percentage of sales is around 9%. Within the next three years, we are envisioning optimizing this at 8%. With our R&D centres of excellence, across 5 unique platforms, we are really excited about the future of our pipeline," said Sonig.

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

[\[Close\]](#)